Transforming how molecular biology translates to human health, personalized medicine and synthetic biology DNA Script was created to revolutionize DNA synthesis with enzymes. Our core R&D efforts have produced innovations in enzyme engineering, surface and nucleotide chemistries, and instrumentation. The integration of these innovations has resulted in SYNTAXTM️, the world’s … [voir plus]

Igyxos develop more effective/efficient infertility treatment for patients Igyxos is a biotechnology company based out of CENTRE INRAe VAL DE LOIRE SITE DE TOURS, NOUZILLY, France. [voir plus]

Bringing a novel class of Butyrophilin-targeted checkpoint modulators into the clinic ImCheck Therapeutics an @Ipsen company designing and developing a new generation of immunotherapeutic antibodies targeting butyrophilins, a novel super-family of immunomodulators. [voir plus]

Innovative personalized therapies targeting TREM-1 for life-threatening inflammatory syndromes such as septic shock Inotrem is a French biopharmaceutical company founded in 2013, with offices in Paris and a technology center in Nancy (France). Our mission is to improve public health by developing a new class of therapeutic solutions targeting the … [voir plus]

Biomorphic Programmable Polymers TISSIUM was founded in 2013 to address one of the most persistent medical challenges since the inception of surgical procedures: to reconstruct damaged tissue and restore its natural function. Since the discovery of our first polymer at the labs of Bob Langer and Jeff Karp at MIT, … [voir plus]

Dynacure is a clinical-stage company focused on developing novel therapies for rare diseases. Dynacure is a clinical-stage company focused on developing and commercializing novel therapies to transform the lives of patients with rare diseases who have limited or no treatment options. Dynacure is developing DYN101, an investigational antisense product candidate … [voir plus]

Développer des thérapies pour les maladies rénales chroniques ENYO Pharma développe des traitements thérapeutiques innovants basés sur des propriétés fibrolytiques et anti-inflammatoires pour les maladies associées à une insuffisance rénale. La société mène actuellement des essais de phase 2 avec son composé phare, le Vonafexor, dans le traitement des maladies … [voir plus]